Research programme: GPR40-GPR120 dual agonists - Advinus Therapeutics

Drug Profile

Research programme: GPR40-GPR120 dual agonists - Advinus Therapeutics

Latest Information Update: 25 Jan 2016

Price : $50

At a glance

  • Originator Advinus Therapeutics
  • Class
  • Mechanism of Action FFAR1 protein stimulants; GPR120 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Research Type 2 diabetes mellitus

Most Recent Events

  • 25 Jan 2016 Early research in Type-2 diabetes mellitus in India (unspecified route)
  • 25 Jan 2016 GPR40-GPR120 dual agonists - Advinus Therapeutics is available for licensing as of 25 Jan 2016. www.advinus.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top